MS Pharma Launches MENA's First Biologics Production Facility in Saudi Arabia
In an exciting development for the biotechnology sector in the Middle East, MS Pharma has recently inaugurated its first biologics manufacturing facility in Saudi Arabia, marking a significant milestone in the region's pharmaceutical landscape. This facility stands as the first of its kind in the Middle East, strategically located to cater to the demands of local and international markets. Approved by the Saudi Food and Drug Authority (SFDA), the facility adheres to the stringent standards set forth by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).
The state-of-the-art plant represents a $50 million investment, aiming to position MS Pharma as a premier provider of biologics in this rapidly expanding market. With a focus on monoclonal antibodies and complex peptides — two of the most sought-after classes of biological treatments worldwide — the facility is set to become a pivotal hub for biopharmaceutical production within the MENA region. In addition to production capabilities, the site features its own bioanalytical laboratories, the first of their kind in the area, eliminating the need to outsource testing services and thereby expediting the launch of crucial treatments.
Ghiath Sukhtian, the Chairman of MS Pharma, highlighted the importance of this facility, stating, “This launch is a critical milestone for MS Pharma and the biopharma landscape in the Middle East and North Africa. We are proud to lead a regional platform for biologics that meets global health care demands while delivering high-quality, complex medications in cooperation with international partners.”
The CEO of MS Pharma, Kalle Känd, further emphasized the strategic vision behind the new facility, saying, “This facility is not just a manufacturing site; it serves as a strategic enabler for global partnerships, offering regional access and manufacturing capacities for international markets.” The plant is expected to facilitate domestic content, promote job creation, and drive technology transfer, which aligns with the Kingdom's Vision 2030 goals.
As Saudi Arabia positions itself to become a key player in the global biopharmaceutical market, this facility leverages industrial incentives and its strategic location to serve not only the Saudi market but also broader regional needs in North Africa, the EU, and beyond. MS Pharma aims to enhance its role as a regional leader in biologics, equipped with the capabilities, capacities, and compliance standards necessary to tap into diverse markets and increase its value as a production and partnership platform.
Founded in 1989 in Amman, Jordan, MS Pharma has grown into a leading multinational pharmaceutical company committed to providing access to high-quality medicines throughout the Middle East and Africa. The company boasts over 2,000 employees across twelve countries and operates five manufacturing sites in Jordan, Algeria, and now Saudi Arabia. MS Pharma’s diverse portfolio includes the development, production, and distribution of generics, complex injection formulations, and biosimilars for an array of therapeutic areas, including oncology, cardiovascular conditions, and central nervous system disorders. Through its endeavors, MS Pharma significantly contributes to improving health outcomes across the region.
This step forward clearly illustrates the company's forward-thinking strategy, placing MS Pharma at the forefront of pharmaceutical innovation and access within the MENA region. As they continue to develop their capabilities, the future looks promising for both MS Pharma and the healthcare landscape in Saudi Arabia and beyond.
The state-of-the-art plant represents a $50 million investment, aiming to position MS Pharma as a premier provider of biologics in this rapidly expanding market. With a focus on monoclonal antibodies and complex peptides — two of the most sought-after classes of biological treatments worldwide — the facility is set to become a pivotal hub for biopharmaceutical production within the MENA region. In addition to production capabilities, the site features its own bioanalytical laboratories, the first of their kind in the area, eliminating the need to outsource testing services and thereby expediting the launch of crucial treatments.
Ghiath Sukhtian, the Chairman of MS Pharma, highlighted the importance of this facility, stating, “This launch is a critical milestone for MS Pharma and the biopharma landscape in the Middle East and North Africa. We are proud to lead a regional platform for biologics that meets global health care demands while delivering high-quality, complex medications in cooperation with international partners.”
The CEO of MS Pharma, Kalle Känd, further emphasized the strategic vision behind the new facility, saying, “This facility is not just a manufacturing site; it serves as a strategic enabler for global partnerships, offering regional access and manufacturing capacities for international markets.” The plant is expected to facilitate domestic content, promote job creation, and drive technology transfer, which aligns with the Kingdom's Vision 2030 goals.
As Saudi Arabia positions itself to become a key player in the global biopharmaceutical market, this facility leverages industrial incentives and its strategic location to serve not only the Saudi market but also broader regional needs in North Africa, the EU, and beyond. MS Pharma aims to enhance its role as a regional leader in biologics, equipped with the capabilities, capacities, and compliance standards necessary to tap into diverse markets and increase its value as a production and partnership platform.
Founded in 1989 in Amman, Jordan, MS Pharma has grown into a leading multinational pharmaceutical company committed to providing access to high-quality medicines throughout the Middle East and Africa. The company boasts over 2,000 employees across twelve countries and operates five manufacturing sites in Jordan, Algeria, and now Saudi Arabia. MS Pharma’s diverse portfolio includes the development, production, and distribution of generics, complex injection formulations, and biosimilars for an array of therapeutic areas, including oncology, cardiovascular conditions, and central nervous system disorders. Through its endeavors, MS Pharma significantly contributes to improving health outcomes across the region.
This step forward clearly illustrates the company's forward-thinking strategy, placing MS Pharma at the forefront of pharmaceutical innovation and access within the MENA region. As they continue to develop their capabilities, the future looks promising for both MS Pharma and the healthcare landscape in Saudi Arabia and beyond.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.